Indian Company Master Data Made Simple
Ishita Drugs And Industries Limited
Established in 1992, Ishita Drugs And Industries Limited has 34 years of operational experience. Its CIN is L24231GJ1992PLC017054, with registration number 17054. It falls under the category of company limited by shares. Authorized share capital stands at ₹6.00 crore. Paid-up capital for the company equals ₹2.99 crore.
The company specializes in manufacture of chemicals and chemical products operations. It is registered in Ahmedabad. Its registered address is Survey No 179/1, Vasna-iyava, Taluka Sanand, Ahmedabad, Gujarat, India, 382210. It is officially listed as an active business entity. The company may be contacted through its official email: ishitadrugs@gmail.com. The leadership team includes Sumit Jagdishprasad Agrawal (CFO).
Company Overview
- CIN
- Date of Incorporation
- 05/02/1992
- Company Status
- Active
- RoC
- Ahmedabad
- Registration Number
- Balance sheet date
- 31/03/2024
- Company Category
- Company limited by shares
- Company Sub Category
- Non-government company
- Listed in Stock Exchange
- Yes
- Class of Company
- Public Limited Company
- LEI Number
- Authorized Capital
- ₹6,00,00,000.00
- Paid up Capital
- ₹2,99,03,000.00
- Activity
- Manufacture Of Chemicals And Chemical Products
- ishitadrugs@gmail.com
- PAN
ISIN Numbers
| ISIN | Security | Interest Rate | Maturity Date | FISN | CFI |
|---|---|---|---|---|---|
| IN8806D01015 | ISHITA DRUGS AND INDUSTRIES LIMITED EQ LISTING/TRADING APPROVAL AWAITED | - | 12/10/2026 | ISHITADRUGS&IND/SH VTG | ESVUFN |
| INE806D01016 | ISHITA DRUGS AND INDUSTRIES LIMITED EQ | - | 12/10/2026 | ISHITADRUGS&IND/SH VTG | ESVUFN |
Balance Sheet
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| Net PPE | ₹263.02L | ₹87.90L | ₹80.46L | ₹88.95L | ₹0.00L |
| Gross PPE | ₹647.69L | ₹483.91L | ₹475.82L | ₹473.14L | ₹0.00L |
| Inventory | ₹92.32L | ₹446.49L | ₹106.42L | ₹159.83L | ₹0.00L |
| Total Debt | ₹8.18L | ₹390.30L | ₹0.00L | ₹96.04L | ₹0.00L |
| Common Stock | ₹299.03L | ₹299.03L | ₹299.03L | ₹299.03L | ₹0.00L |
| Current Debt | ₹4.73L | ₹381.35L | ₹0.00L | ₹96.04L | ₹0.00L |
| Share Issued | ₹29.90L | ₹29.90L | ₹29.90L | ₹29.90L | ₹0.00L |
| Total Assets | ₹1,260.37L | ₹1,629.58L | ₹1,080.87L | ₹1,140.72L | ₹0.00L |
| Capital Stock | ₹299.03L | ₹299.03L | ₹299.03L | ₹299.03L | ₹0.00L |
| Long Term Debt | ₹3.45L | ₹8.94L | ₹0.00L | ₹0.00L | ₹0.00L |
| Current Assets | ₹954.22L | ₹1,498.35L | ₹965.70L | ₹1,017.76L | ₹0.00L |
| Prepaid Assets | ₹3.14L | ₹3.24L | ₹1.77L | ₹2.56L | ₹0.00L |
| Working Capital | ₹855.36L | ₹957.87L | ₹878.98L | ₹796.46L | ₹0.00L |
| Invested Capital | ₹1,164.99L | ₹1,469.26L | ₹992.15L | ₹1,013.35L | ₹0.00L |
| Other Properties | ₹21.99L | ₹21.99L | ₹21.99L | ₹34.94L | ₹0.00L |
| Common Stock Equity | ₹1,156.81L | ₹1,078.96L | ₹992.15L | ₹917.30L | ₹0.00L |
| Net Tangible Assets | ₹1,156.81L | ₹1,078.96L | ₹992.15L | ₹917.30L | ₹0.00L |
| Tangible Book Value | ₹1,156.81L | ₹1,078.96L | ₹992.15L | ₹917.30L | ₹0.00L |
| Current Liabilities | ₹98.85L | ₹540.48L | ₹86.73L | ₹221.30L | ₹0.00L |
| Stockholders Equity | ₹1,156.81L | ₹1,078.96L | ₹992.15L | ₹917.30L | ₹0.00L |
| Other Equity Interest | ₹1.65L | ₹1.65L | ₹1.65L | ₹1.65L | ₹0.00L |
| Total Capitalization | ₹1,160.26L | ₹1,087.91L | ₹992.15L | ₹917.30L | ₹0.00L |
| Ordinary Shares Number | ₹29.90L | ₹29.90L | ₹29.90L | ₹29.90L | ₹0.00L |
| Other Non Current Assets | -₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | -₹0.00L |
| Total Non Current Assets | ₹306.16L | ₹131.24L | ₹115.17L | ₹122.96L | ₹0.00L |
| Cash And Cash Equivalents | ₹14.56L | ₹56.84L | ₹182.53L | ₹60.55L | ₹0.00L |
| Construction In Progress | ₹174.73L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Accumulated Depreciation | -₹384.67L | -₹396.01L | -₹395.36L | -₹384.19L | ₹0.00L |
| Other Short Term Investments | ₹665.35L | ₹778.05L | ₹604.96L | ₹594.54L | ₹0.00L |
| Machinery Furniture Equipment | ₹370.22L | ₹381.18L | ₹373.08L | ₹357.46L | ₹0.00L |
| Total Equity Gross Minority Interest | ₹1,156.81L | ₹1,078.96L | ₹992.15L | ₹917.30L | ₹0.00L |
| Total Liabilities Net Minority Interest | ₹103.56L | ₹550.62L | ₹88.71L | ₹223.41L | ₹0.00L |
| Current Debt And Capital Lease Obligation | ₹4.73L | ₹381.35L | ₹0.00L | ₹96.04L | ₹0.00L |
| Long Term Debt And Capital Lease Obligation | ₹3.45L | ₹8.94L | ₹0.00L | ₹0.00L | ₹0.00L |
| Cash Cash Equivalents And Short Term Investments | ₹679.91L | ₹834.89L | ₹787.49L | ₹655.09L | ₹0.00L |
| Total Non Current Liabilities Net Minority Interest | ₹4.71L | ₹10.14L | ₹1.99L | ₹2.11L | ₹0.00L |
Cash Flow
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 |
|---|---|---|---|---|
| Free Cash Flow | ₹206.85L | -₹382.14L | ₹209.40L | -₹303.16L |
| Changes In Cash | -₹212.98L | ₹2.40L | ₹138.15L | -₹125.36L |
| End Cash Position | ₹270.40L | ₹483.38L | ₹480.98L | ₹342.83L |
| Financing Cash Flow | -₹380.70L | ₹432.74L | -₹86.95L | ₹104.97L |
| Investing Cash Flow | -₹224.20L | -₹66.63L | ₹13.03L | ₹59.42L |
| Operating Cash Flow | ₹391.93L | -₹363.71L | ₹212.08L | -₹289.75L |
| Capital Expenditure | -₹185.08L | -₹18.42L | -₹2.68L | -₹13.42L |
| Beginning Cash Position | ₹483.38L | ₹480.98L | ₹342.83L | ₹468.19L |
| Other Cash Adjustment Outside Changein Cash | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
Income Statement
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 |
|---|---|---|---|---|
| EBIT | ₹111.72L | ₹118.98L | ₹104.95L | ₹81.59L |
| EBITDA | ₹121.67L | ₹129.96L | ₹116.12L | ₹94.52L |
| Basic EPS | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Net Income | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
| Diluted EPS | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Gross Profit | ₹389.29L | ₹372.19L | ₹347.54L | ₹307.39L |
| Pretax Income | ₹108.00L | ₹115.51L | ₹98.73L | ₹77.94L |
| Tax Provision | ₹30.15L | ₹28.71L | ₹23.88L | ₹20.20L |
| Total Revenue | ₹1,466.02L | ₹1,499.73L | ₹1,518.76L | ₹1,207.23L |
| Cost Of Revenue | ₹1,076.73L | ₹1,127.53L | ₹1,171.22L | ₹899.84L |
| Total Expenses | ₹1,399.42L | ₹1,410.56L | ₹1,439.08L | ₹1,143.99L |
| Interest Income | ₹25.09L | ₹28.46L | ₹18.06L | ₹14.28L |
| Interest Expense | ₹3.71L | ₹3.46L | ₹6.23L | ₹3.65L |
| Operating Income | ₹66.61L | ₹89.16L | ₹79.68L | ₹63.25L |
| Tax Rate For Calcs | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Normalized EBITDA | ₹121.67L | ₹129.96L | ₹116.12L | ₹94.52L |
| Normalized Income | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
| Operating Expense | ₹322.69L | ₹283.03L | ₹267.86L | ₹244.15L |
| Operating Revenue | ₹1,466.02L | ₹1,499.73L | ₹1,518.76L | ₹1,207.23L |
| Net Interest Income | ₹19.17L | ₹21.24L | ₹9.09L | ₹8.93L |
| Total Unusual Items | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Basic Average Shares | ₹29.90L | ₹29.90L | ₹29.90L | ₹29.90L |
| Diluted Average Shares | ₹29.90L | ₹29.90L | ₹29.90L | ₹29.90L |
| Total Other Finance Cost | ₹2.21L | ₹3.76L | ₹2.75L | ₹1.71L |
| Net Income Extraordinary | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Other Operating Expenses | ₹57.75L | ₹9.24L | ₹8.31L | ₹7.57L |
| Reconciled Depreciation | ₹9.96L | ₹10.98L | ₹11.17L | ₹12.93L |
| Reconciled Cost Of Revenue | ₹1,076.73L | ₹1,127.53L | ₹1,171.22L | ₹899.84L |
| Rent Expense Supplemental | ₹19.03L | ₹20.89L | ₹23.62L | ₹30.38L |
| Tax Effect Of Unusual Items | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Interest Income Non Operating | ₹25.09L | ₹28.46L | ₹18.06L | ₹14.28L |
| Selling And Marketing Expense | ₹37.28L | ₹48.82L | ₹45.27L | ₹28.90L |
| Interest Expense Non Operating | ₹3.71L | ₹3.46L | ₹6.23L | ₹3.65L |
| Net Income Common Stockholders | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
| Net Income Continuous Operations | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
| Diluted NIAvailto Com Stockholders | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
| General And Administrative Expense | ₹60.74L | ₹58.67L | ₹45.59L | ₹36.01L |
| Selling General And Administration | ₹98.02L | ₹107.49L | ₹90.86L | ₹64.91L |
| Net Income Discontinuous Operations | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Otherunder Preferred Stock Dividend | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Total Unusual Items Excluding Goodwill | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Net Non Operating Interest Income Expense | ₹19.17L | ₹21.24L | ₹9.09L | ₹8.93L |
| Net Income Including Noncontrolling Interests | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
| Net Income From Continuing And Discontinued Operation | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
| Net Income From Continuing Operation Net Minority Interest | ₹77.85L | ₹86.81L | ₹74.85L | ₹57.74L |
Company Performance (FY23–FY26)
Directors
| Appointment | Director name | DIN | Designation | |
|---|---|---|---|---|
| 05/02/1992 | Jagdishprasad Agrawal Gokulchand | 01031687 | Managing Director | View other directorships |
| 05/02/1992 | Abha Agrawal Jagdishprasad | 01589479 | Director | View other directorships |
| 13/11/2018 | Sumit Jagdishprasad Agrawal | *****7406J | CFO | |
| 12/11/2019 | Arvind Vilasrao Sapkal | 08607096 | Director | View other directorships |
| 04/02/2021 | Srushti Pandya | *****5733H | Company Secretary | |
| 13/08/2024 | Dhwani Jaspalsinh Solanki | 10299290 | Director | View other directorships |
Business Network
Directors 6
- Jagdishprasad Agrawal GokulchandManaging Director
- Dhwani Jaspalsinh SolankiDirector
- Arvind Vilasrao SapkalDirector
- Abha Agrawal JagdishprasadDirector
- Srushti PandyaCompany Secretary
- Sumit Jagdishprasad AgrawalCFO
Latest Documents
| Date | Title | Size |
|---|---|---|
| 21/11/2024 | Form MGT-7-21112024 | - |
| 12/11/2024 | Form AOC-4(XBRL)-28102024 | - |
Similar Companies
| Company | CIN | Address |
|---|---|---|
| Dabur India Limited | L24230DL1975PLC007908 | 8/3 Asaf Ali Road, New Delhi, Delhi, India, 110002 |
| Gujchem Distillers India Limited | L24230GJ1939PLC002480 | - |
| Ind Swift Limited | L24230CH1986PLC006897 | 781industrial Area Phase Ii, Chandigarh, Chandigarh, India, 160002 |
| Lyka Labs Limited | L24230GJ1976PLC008738 | 4801/b & 4802/a Gidc Indutrail Estate, Ankleshwar, Gujarat, India, 393002 |
| Torrent Pharmaceuticals Ltd | L24230GJ1972PLC002126 | Torrent Houseoff Ashram Road Navarangpura 9, Ahmedabad, Gujarat, India, 000000 |
Address
Frequently Asked Questions
The current board member of Ishita Drugs And Industries Limited are:
- Jagdishprasad Agrawal Gokulchand
- Abha Agrawal Jagdishprasad
- Arvind Vilasrao Sapkal
- Dhwani Jaspalsinh Solanki